Skip to content
DataLookout
Menu

NCT07912268

Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Dose-limiting toxicity(DLT) (Dose escalation)
Timeframe: During the first cycle treatment with SIM0518
Adverse event Rate
Timeframe: Up to approximately 24 months
Adverse event Severity
Timeframe: Up to approximately 24 months
Serious Adverse Event Rate
Timeframe: Up to approximately 24 months
Serious Adverse Event Severity
Timeframe: Up to approximately 24 months
Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months

Secondary (16)

Pharmacokinetics: The area under the curve (AUC)
Pharmacokinetics:Peak concentration (Cmax)
Pharmacokinetics: T1/2
Pharmacokinetics: Tmax
Pharmacokinetics: Ctrough
Show 11 moreShow less
Duration of Response (DOR)
Disease Control Rate (DCR)
Time To Response (TTR)
Intracranial Objective Response Rate (IC-ORR)
Intracranial Disease Control Rate (IC-DCR)
Intracranial Duration of Response (IC-DOR)
Intracranial Time To Response (IC-TTR)
Intracranial Progression-Free Survival (IC-PFS)
Objective Response Rate (ORR) (Part 1)
Number of Participants with Abnormal Laboratory Values
Tolerability

Arms and interventions

SIM0518Experimental

SIM0518 Capsule, Use as specified in the Protocol

SIM0518+MidazolamExperimental

SIM0518 Capsuleand Midazolam Oral Solution ,Use as Specified in the Protocol

SIM0518+BupropionExperimental

SIM0518 Capsule and Bupropion Hydrochloride Tablets ,Use as Specified in the Protocol

SIM0518+RepaglinideExperimental

SIM0518 Capsuleand Repaglinide Tablets ,Use as Specified in the Protocol

SIM0518+TolbutamideExperimental

SIM0518 Capsule, and Tolbutamid Tablets,Use as Specified in the Protocol

SIM0518+FexofenadineExperimental

SIM0518 Capsule and Fexofenadine Hydrochloride Tablets ,Use as Specified in the Protocol

SIM0518+Rosuvastatin TabletsExperimental

SIM0518 Capsule and Rosuvastatin Calcium Tablets ,Use as Specified in the Protocol

Drugs: SIM0518, SIM0518+Bupropion, SIM0518+Midazolam, SIM0518+Repaglinide, SIM0518+Tolbutamide, SIM0518+Fexofenadine, SIM0518+ Rosuvastatin Calcium

Sites

8 sites in 1 country